Sort
39,280 grants matching “leukemia”
Differentiating Agents in Hematologic Malignancies
$324,900Dana-Farber Cancer Institute · R01 · FY2003 · CA
A Novel Strategy for Defining and Targeting Cancer Addiction to Anti-Apoptotic BC
$324,900Anthony G Letai · Dana-Farber Cancer Inst · R01 · FY2008 · CA
Recognition and Segregation of Broken Chromosomes
$324,866University Of California San Francisco · R01 · FY2004 · GM
Project 2: Preclinical Drug Approaches to Chronic Graft-vs.-Host-Disease Prevention and Treatment
$324,847Bruce R. Blazar · Dana-Farber Cancer Inst · P01 · FY2017 · CA
Project 2: Preclinical Drug Approaches to Chronic Graft-vs.-Host-Disease Prevention and Treatment
$324,847Bruce R. Blazar · Dana-Farber Cancer Inst · P01 · FY2018 · CA
Project 2: Preclinical Drug Approaches to Chronic Graft-vs.-Host-Disease Prevention and Treatment
$324,847Bruce R. Blazar · Dana-Farber Cancer Inst · P01 · FY2016 · CA
ANIMAL MODELS OF MOLECULAR PATHOGENSIS OF HTLV-1
$324,840Ohio State University · R01 · FY2003 · RR
Pretargeted Radioimmunotherapy for Hematologic Malignancies
$324,833Oliver W. Press · Fred Hutchinson Cancer Research Center · P01 · FY2011 · CA
Development of Therapeutic CD59 inhibitor for treating B-cell malignancies
$324,825Xuebin Qin · Temple Univ Of The Commonwealth · R01 · FY2014 · CA
Impact of CREB-driven mechanism in shaping the tumor-immune landscape
$324,760Nagaraj S. Nagathihalli · University Of Miami School Of Medicine · R01 · FY2023 · CA
DISCOVERY OF SMALL MOLECULAR ACTIVATORS OF NR4A ORPHAN NUCLEAR RECEPTORS
$324,738Orla M. Conneely · Baylor College Of Medicine · R01 · FY2012 · CA
Infectious origins of childhood leukemia
$324,738Markus Mãschen · University Of California, San Francisco · R01 · FY2012 · CA
DISCOVERY OF SMALL MOLECULAR ACTIVATORS OF NR4A ORPHAN NUCLEAR RECEPTORS
$324,738Orla M. Conneely · Baylor College Of Medicine · R01 · FY2016 · CA
DISCOVERY OF SMALL MOLECULAR ACTIVATORS OF NR4A ORPHAN NUCLEAR RECEPTORS
$324,738Orla M. Conneely · Baylor College Of Medicine · R01 · FY2015 · CA
Discovery of clinically distinct CLL subgroups by integrative mapping of large-scale CLL genetic, expression and clinical data
$324,717Gad A Getz · Dana-Farber Cancer Inst · P01 · FY2019 · CA
Immunoglobulin and T Cell Receptor Gene Assembly
$324,711David G. Schatz · Yale University · R37 · FY2009 · AI
Tyrosine Kinase Signaling in Cancer Cell Metabolism
$324,703Jing Chen · Emory University · R01 · FY2010 · CA
Consumer-based meditation app, Calm, for treatment of sleep disturbance in hematological cancer patients
$324,702Jennifer Lynne Huberty · University Of Texas Hlth Science Center · R01 · FY2024 · CA
Flt3: Role in Leukemia Stem Cells
$324,674Donald Small · Johns Hopkins University · P01 · FY2008 · CA
Targeting the Metabolic Regulator SIRT5 in Acute Myeloid Leukemia
$324,666Michael W Deininger · Versiti Wisconsin, Inc. · R01 · FY2021 · CA
Eastern Cooperative Oncology Group
$324,657Tufts Medical Center · U10 · FY2005 · CA
The pluripotency regulator Prdm14 initiates cancer by epigenetic mechanisms
$324,656Monica Jean Justice · Hospital For Sick Chldrn (Toronto) · R01 · FY2017 · CA
Tyrosine Kinase Pathways in Rheumatoid Arthritis
$324,651William H Robinson · Palo Alto Veterans Instit For Research · R01 · FY2007 · AR
Identification of Tissue Specific Stem Cells
$324,648Saul J Sharkis · Johns Hopkins University · P01 · FY2008 · CA
SUMO modification and cancer therapy
$324,634Yuan Chen · Beckman Research Institute/City Of Hope · R01 · FY2014 · GM